If you are a PE sponsor, operating partner or mid-market CEO searching for value creation diagnostic cost, you are probably not looking for a theoretical pricing page. You have a live asset, a potential acquisition, a board conversation, or a first-100-days problem. You need to know what it should cost to get an experienced operator to look under the bonnet, separate signal from theatre, and give you a plan you can actually use.
In my experience, the buyer is rarely asking only, 'What is the fee?' The real question is: 'How much should I spend before I have conviction?' That is a better question. A diagnostic can be a cheap memo, a structured 100-day value creation plan, or a months-long transformation review. Those are not the same product, even if the slide titles look similar.
I work as a retained advisor, fractional operating partner and technology advisor alongside sponsors and management teams. I am not selling a large delivery bench as the answer to every problem. The diagnostic is the part where I help decide what matters, what does not, what sequence makes sense, and where execution capacity is justified afterwards.
What buyers actually mean by value creation diagnostic cost
When sponsors search this term, I usually see one of five situations behind it:
- Pre-deal conviction: the deal team wants to know whether a target's technology, operating model or digital revenue story supports the investment thesis before signing or final bids.
- Post-close triage: the business has closed, the management team is busy, and the sponsor needs a sharper 100-day agenda than 'improve sales and modernise systems'.
- Underperformance: EBITDA, churn, delivery margin or roadmap velocity is off plan, and the board needs an independent second opinion.
- Platform build: the sponsor is backing a management team to professionalise technology, data, AI, product, pricing or go-to-market operations without over-hiring too early.
- Exit preparation: the company needs to clean up technical debt, reporting, security posture, platform reliability or operating narrative before diligence starts.
Each situation has a different price tolerance because the decision at stake is different. A two-page view before an IC discussion should not cost the same as a full operating plan across technology, product, data and commercial workflows. Equally, saving money on the diagnostic can be expensive if it leaves the board with vague recommendations and no owner, sequence or trade-off.
Typical cost bands and what drives them
I would think about value creation diagnostic cost in bands rather than fixed menu pricing. The numbers below are not market statistics; they are practical budgeting ranges I see in conversations with sponsors and CEOs.
1. Written second opinion: low four figures
This is a focused written brief: one issue, limited material, clear question. For example: 'Is this product roadmap credible for the next 12 months?' or 'Does the platform architecture create a major investment risk?' The output is usually a concise memo with risks, observations and next questions. It is useful when the sponsor already has the material and needs senior judgement quickly.
2. Focused diagnostic: roughly £8k-£25k
This is where a value creation diagnostic becomes more substantive. It may include management interviews, document review, product and technology assessment, operating cadence review, and a prioritised set of initiatives. It is usually appropriate when the question is narrow enough to answer in one to three weeks but important enough to require more than a call.
3. 100-day value creation plan: roughly £15k-£50k+
A proper 100-day plan is not just a diagnostic. It turns findings into initiatives, owners, sequencing, dependencies and board-level milestones. Cost moves up when the work spans several functions: technology, product, sales operations, data, AI enablement, pricing, delivery efficiency and management reporting. It also moves up when the output must be ready for the board, the lender pack, or the first post-close operating cadence.
4. Retained fractional advisory: monthly retainer
Sometimes the correct answer is not a one-off report. If the sponsor wants a standing second opinion for the first quarter or the CEO needs help making trade-offs every week, a fractional retainer is cleaner. The cost depends on cadence, access and intensity: monthly board advisory is different from weekly operating support through a turnaround or integration.
The cheap diagnostic is the one that prevents a bad hire, a false roadmap, a weak diligence conclusion or six months of unfocused execution.
The main cost drivers
The fee is usually shaped by five factors.
- Scope: A technology-only diagnostic costs less than a full operating review across product, sales, data, engineering and customer success.
- Access: Clean data, direct management access and organised documentation reduce cost. Fragmented systems and defensive stakeholders increase it.
- Urgency: A five-day diligence sprint requires concentrated senior attention. A slower advisory cycle can be more efficient if the decision is not urgent.
- Output standard: A board-ready plan with initiatives, risks, owners and financial implications takes more work than a verbal debrief.
- Implementation proximity: If the diagnostic must connect directly to execution, hiring, vendor selection or technology remediation, the work needs more precision.
The mistake I see is comparing providers by day rate while ignoring whether the advisor has enough pattern recognition to compress the work. A cheaper team spending weeks producing generic findings is not necessarily cheaper than one experienced operator getting to the operating bottleneck quickly.
A decision framework for budgeting the diagnostic
Here is the framework I use when deciding what level of diagnostic is justified.
Step 1: Name the decision
Do not start with 'we need a diagnostic'. Start with the decision. Are you deciding whether to buy, whether to replace a CTO, whether to fund a platform rebuild, whether to integrate acquisitions, or whether to reset the first 100 days? The sharper the decision, the easier it is to price the work.
Step 2: Define the cost of being wrong
If the consequence of being wrong is a missed board update, a written brief may be enough. If the consequence is underwriting the wrong capex plan, delaying integration, or pursuing a false AI strategy, pay for more depth. The diagnostic cost should be proportional to decision risk, not to procurement habit.
Step 3: Separate discovery from planning
Discovery tells you what is true. Planning tells you what to do next. Many diagnostics fail because they stop at discovery: 'data is fragmented', 'technical debt is high', 'sales operations need improvement'. That is not enough. A useful 100-day plan says what to do in weeks 1-2, 3-6 and 7-13, what not to do, who owns each stream, and what the board should track.
Step 4: Decide who will use the output
A CEO needs operating clarity. A sponsor needs investment implications. A board needs a small number of measurable priorities. A CTO needs technical sequencing and resourcing trade-offs. If the output has to serve all four audiences, budget for synthesis, not just analysis.
Step 5: Decide whether execution capacity is needed
Sometimes the plan reveals that a company needs hands-on delivery: data cleanup, platform remediation, reporting rebuilds, AI workflow implementation, CRM hygiene, engineering governance or vendor replacement. That is a separate decision. DevriX, my company, is where execution capacity can come from after a plan is agreed, but the advisory judgement comes first. I would not lead with a delivery pod before the problem is properly diagnosed.
Short comparison of options
There are several ways to buy this work. None is universally right.
- Independent operating advisor: Best when you need senior judgement, direct access and low politics. You get one accountable point of view rather than a pyramid of analysts. The trade-off is capacity; a single advisor must be selective about scope.
- Large consulting firm: Useful for broad transformation programmes, heavy stakeholder management and large-scale documentation. The trade-off is cost, speed and the risk of a generic operating model that looks polished but is hard to execute.
- Technical diligence boutique: Strong for pre-close code, architecture, security and product diligence. The trade-off is that they may stop short of commercial value creation or post-close operating cadence.
- Internal management team: Cheapest on paper and often essential for context. The trade-off is bias, bandwidth and the difficulty of challenging existing plans.
- Interim executive: Useful when you already know the function needs leadership. The trade-off is commitment; if the problem is not yet clear, an interim hire may become an expensive answer to the wrong question.
For many mid-market situations, the strongest pattern is a senior independent diagnostic first, followed by targeted execution only where the plan proves it is needed. That keeps the first spend disciplined.
When a value creation diagnostic is the wrong tool
A diagnostic is not always the right move. I would avoid it in several cases.
- You already know the decision: If the board has decided to replace a system, appoint a leader or shut down a product line, do not buy a diagnostic to create cover. Spend the money on execution planning.
- Management will not engage: If the CEO or functional leaders refuse access, the work becomes theatre. You may still need a board-level intervention, but call it that.
- The question is too broad: 'Find value creation opportunities' is not a scope. It invites a long list of obvious ideas. Start with the investment thesis and the constraint.
- The sponsor wants validation, not judgement: If the answer must be positive, do not hire an advisor. A useful diagnostic may challenge the plan, the roadmap or the management narrative.
- Cash is too tight for follow-through: If there is no budget, management capacity or board appetite to act, a diagnostic will only document frustration.
The wrong diagnostic creates noise. The right diagnostic creates decisions.
What a good diagnostic should produce
A serious value creation diagnostic should not end with a laundry list. At minimum, I would expect:
- Current-state view: where the company is strong, fragile or exposed.
- Value levers: the few initiatives that connect to revenue growth, margin, retention, cash conversion, risk reduction or exit readiness.
- Sequence: what happens now, next and later.
- Owners: who is accountable inside the business.
- Resourcing view: what requires internal time, external help, new hires or vendor changes.
- Board cadence: what should be reviewed monthly for the first 100 days.
- Stop-doing list: projects that consume attention without changing enterprise value.
The stop-doing list matters. Many portfolio companies are not short of ideas; they are short of sequencing and management attention. A good diagnostic protects focus.
How I would approach this
If you are early in a deal and only need a fast read on technology, product or operating risk, I would start smaller. A focused pre-close review or written second opinion can be enough to frame the next diligence question.
If you are post-close, entering the first board cycle, or trying to turn diligence findings into operating action, I would build a 100-Day Value Creation Plan. That means interviewing the right people, reviewing the operating evidence, identifying the few value levers that matter, and converting them into a board-ready sequence for the first quarter.
If the business needs continuing judgement after that, I would move to a Fractional Retainer rather than pretending a single deck will manage the trade-offs. In that role, I sit alongside the CEO, sponsor or operating partner as a standing second opinion: challenging priorities, reviewing progress, and helping decide when execution capacity is actually warranted.
My bias is simple: spend enough on the diagnostic to make the next decision safer, but not so much that the diagnostic becomes the project. The best value creation work is practical, sequenced and owned. It gives management a clear operating path and gives the sponsor a sharper view of where enterprise value will actually move.